Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) was last seen gaining almost 20 percent to $11.23 per share on Nasdaq, it was a trading session that was also characterized with high volume trading. The company is concerned with the development of drugs targeted at the treatment of brain and eye degeneration due to old age. Its initial drug focus was for the treatment of Alzheimer’s disease. But during the course of 2012, the company took on more burden of developing therapies for Huntington’s and Parkinson’s diseases.Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares after opening at $2.70 moved to $2.71 on last trade day and at the end of the day closed at $2.30. Company price to sales ratio in past twelve months was calculated as 321.62 and price to cash ratio as 5.51. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) showed a negative weekly performance of -79.34%.
The Ventrus Biosciences Inc (NASDAQ:VTUS) on Feb. 12 announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). In this randomized double blind trial comparing diltiazem 2% cream versus placebo cream in 434 subjects in 90 centers globally, both treatment arms demonstrated a clinically meaningful improvement. The diltiazem 2% treatment arm demonstrated no significant improvement compared to placebo in the primary endpoint of average of worst anal pain associated with or following defecation. The mean of worst AF-related pain score at baseline was 7.09 for diltiazem 2% and 7.18 for placebo, decreasing to 3.81 (-3.28 difference) and 3.72 (-3.46 difference) respectively. Ventrus Biosciences Inc (NASDAQ:VTUS) shares fell -6.67% in last trading session and ended the day on $1.19. VTUS return on equity ratio is recorded as -60.40% and its return on assets is -55.60%. Ventrus Biosciences Inc (NASDAQ:VTUS) yearly performance is -59.93%.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer.Onconova Therapeutics Inc (NASDAQ:ONTX) shares moved down -2.05% in last trading session and was closed at $6.21, while trading in range of $6.12-$6.49. Onconova Therapeutics Inc (NASDAQ:ONTX) year to date performance is -45.91%.
In the fourth quarter of 2013, Bio-Path Holdings Inc (NASDAQ:BPTH) initiated preclinical testing of its lead product candidate, Liposomal Grb-2, into two additional indications: triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates. During the quarter, Bio-Path also initiated preclinical testing of Liposomal Grb-2 in combination with front-line therapies for blood cancers. This testing is being performed to provide supporting evidence for Bio-Path’s Phase II clinical trial program, which is currently being planned to evaluate Liposomal Grb-2 in combination with front-line therapies.
Bio-Path Holdings Inc (NASDAQ:BPTH) weekly performance is -16.30%. On last trading day company shares ended up $2.26. Bio-Path Holdings Inc (NASDAQ:BPTH) distance from 50-day simple moving average is -41.63%. Analysts mean target price for the company is $3.00.